Ganirelix Acetate Research Grade Peptide (GnRH Antagonist) Supplier — UPOR Biotech
Ganirelix acetate (ORG 37462, CAS 129311-55-3) is a synthetic decapeptide GnRH/LHRH antagonist that produces immediate, reversible suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through high-affinity competitive blockade of the pituitary GnRH receptor — without the initial “flare-up” characteristic of GnRH agonists. The reference antagonist for controlled ovarian hyperstimulation (COH) in assisted-reproduction research, supplied as a lyophilized diacetate salt. Research peptide supplier — premium ganirelix acetate from UPOR Biotech.
Request a QuoteProduct Overview
Ganirelix acetate (CAS 129311-55-3; ORG 37462) is a synthetic decapeptide GnRH/LHRH antagonist with the sequence Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-Tyr-D-hArg(Et₂)-Leu-hArg(Et₂)-Pro-D-Ala-NH₂, featuring diethylated D-arginine residues at positions 6 and 8 that confer high-affinity competitive binding. It is supplied as the lyophilized diacetate salt (free base C₈₀H₁₁₃ClN₁₈O₁₃, MW 1570.32 g/mol; diacetate C₈₄H₁₂₁ClN₁₈O₁₇, MW 1690.42 g/mol). Mechanistically, ganirelix is a potent competitive antagonist at the pituitary GnRH receptor — it produces immediate, reversible suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), preventing the premature LH surge in controlled ovarian stimulation (COH) — and critically, it does so without the initial “flare-up” release of gonadotropins that characterizes GnRH agonists. Clinically referenced as Orgalutran® in assisted-reproduction protocols, ganirelix is cited here strictly as RUO reference material — UPOR Biotech supplies it for research applications only, not for human diagnostic or therapeutic use.
As the standard antagonist for controlled ovarian hyperstimulation (COH) research, ganirelix acetate is positioned across IVF/assisted-reproduction protocols, premature LH surge prevention studies, hormone-sensitive cancer research, and hypothalamic-pituitary-gonadal axis (HPGA) pharmacology. Its diethyl-arginine architecture delivers fast onset (gonadotropin suppression within hours) and rapid reversibility on GnRH antagonist wash-out — an operational advantage over GnRH agonists for short-duration protocols. All lots are produced under ISO 9001, cGMP, and FDA facility registration with full documentation, including COA, MSDS, HPLC purity ≥98.0%, MS confirmation, and endotoxin ≤1.0 EU/mg. The lyophilized diacetate salt is supplied in 1 mg, 5 mg, 10 mg, and 50 mg vials. Research Use Only (RUO) — not for human diagnostic or therapeutic use.
Ganirelix vs Cetrorelix — Two GnRH Antagonists for Fertility Research
Both ganirelix (ORG 37462) and cetrorelix (SB-75) are synthetic decapeptide GnRH antagonists that competitively block the pituitary GnRH receptor to prevent the premature LH surge in fertility research. The distinction is structural and positional: ganirelix carries diethyl-arginine (hArg(Et₂)) substitutions at positions 6 and 8 and is the standard antagonist for controlled ovarian hyperstimulation (COH) research, while cetrorelix has a broader oncology research profile, with investigation extending to hormone-dependent tumors. UPOR Biotech supplies both as Research Grade (RUO) peptides with full analytical documentation.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | Ganirelix Acetate (ORG 37462) — Research Grade (RUO), decapeptide GnRH antagonist |
| Synonyms | Ganirelix; ORG 37462; Ganirelix Acetate; Ganirelix (acetate salt) |
| CAS Number | 129311-55-3 |
| Molecular Formula | C₈₄H₁₂₁ClN₁₈O₁₇ (diacetate salt); free base C₈₀H₁₁₃ClN₁₈O₁₃ |
| Molecular Weight | 1690.42 g/mol (diacetate) / 1570.32 g/mol (free base) |
| Salt Form | Diacetate |
| Peptide Class | Synthetic decapeptide GnRH/LHRH antagonist (ORG 37462) |
| Peptide Length | 10 amino acid residues (decapeptide) |
| Sequence | Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-Tyr-D-hArg(Et₂)-Leu-hArg(Et₂)-Pro-D-Ala-NH₂ |
| Mechanism of Action | Competitive GnRH receptor antagonist — immediate, reversible suppression of LH and FSH; no agonist flare-up |
| Receptor Target | Pituitary GnRH receptor (GNRHR) |
| Purity (HPLC) | ≥98.0% |
| Peptide Content | ≥85% (by nitrogen determination) |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water, saline, and aqueous buffers at physiological pH; DMSO for concentrated stock solutions |
| Endotoxin Level | ≤1.0 EU/mg |
| Water Content | ≤5.0% (Karl Fischer) |
| Counter-Ion | Acetate |
| pH | 3.5 – 5.0 (1 mg/mL in water) |
| Heavy Metals | ≤10 ppm |
| Storage | -20°C, desiccated, protected from light |
| Grade | Research Grade (RUO) |
| Applications | IVF/assisted reproduction research, COH protocols, premature LH surge prevention, hormone-sensitive cancer research, HPGA pharmacology |
| Certifications | ISO 9001:2015, cGMP, FDA facility registration |
| Packaging | 1 mg / 5 mg / 10 mg / 50 mg lyophilized vials (bulk up to 500 mg) |
| Shelf Life | 2 years (stored at -20°C) |
| Legal Status | For research use only (RUO) |
| Disclaimer | Research Use Only (RUO) — not for human diagnostic or therapeutic use |
Key Benefits — Ganirelix Acetate
Potent GnRH Receptor Antagonism
Ganirelix is a high-affinity competitive antagonist at the pituitary GnRH receptor (GNRHR), with diethylated D-arginine residues at positions 6 and 8 driving potent binding. It delivers immediate, reversible suppression of LH and FSH — the defining pharmacology of a true GnRH antagonist, without the agonistic flare-up of GnRH analogues.
GnRH Receptor AntagonistImmediate LH Surge Prevention in COH
In controlled ovarian hyperstimulation (COH) research, ganirelix blocks the premature LH surge that would otherwise trigger early ovulation. Its rapid onset and quick reversibility allow flexible mid-cycle administration, mirroring the reference antagonist used in assisted-reproduction protocols.
LH Surge PreventionStable Diacetate Salt Lyophilized Form
Supplied as a lyophilized diacetate salt (C₈₄H₁₂₁ClN₁₈O₁₇, MW 1690.42 g/mol) for enhanced stability and solubility. The freeze-dried white to off-white powder reconstitutes readily in water, saline, or aqueous buffers, with 2-year stability at -20°C.
Lyophilized Diacetate≥98% HPLC Purity Research Peptide
Every lot is released with ≥98.0% HPLC purity, ≥85% peptide content, and ≤1.0 EU/mg endotoxin. Full documentation — COA, MSDS, HPLC, and MS confirmation — accompanies every shipment, manufactured under ISO 9001 and cGMP.
≥98% HPLCApplications
IVF & Controlled Ovarian Hyperstimulation Research
Simulation of COH protocols where ganirelix suppresses endogenous LH/FSH to control follicular development and prevent premature ovulation in assisted-reproduction model systems.
Premature LH Surge Prevention Studies
Mid-cycle GnRH antagonist administration to investigate suppression of the LH surge and its consequences on oocyte maturation and cycle outcomes.
Hormone-Sensitive Cancer Research
Blockade of GnRH-mediated gonadotropin signaling to study downstream hormone-dependent growth in reproductive-tract and endocrine-sensitive research models.
Hypothalamic-Pituitary-Gonadal Axis Pharmacology
Probing GnRH receptor pharmacology and HPGA feedback regulation through competitive antagonism of endogenous GnRH at the pituitary.
Gonadotropin Assay & Endocrinology Studies
Use as a reference GnRH antagonist in LH/FSH assay development, receptor-binding studies, and endocrinology validation panels.
Peptide Reference Standard & Assay Development
Analytical reference material for HPLC, LC-MS, and bioassay standardization in reproductive peptide research.
Frequently Asked Questions
Ganirelix acetate (ORG 37462) is a synthetic decapeptide GnRH/LHRH antagonist — the acetate salt of the free-base peptide C₈₀H₁₁₃ClN₁₈O₁₃ (MW 1570.32), supplied as the diacetate C₈₄H₁₂₁ClN₁₈O₁₇ (MW 1690.42). It works by competitively blocking the pituitary GnRH receptor, producing immediate, reversible suppression of LH and FSH — preventing the premature LH surge in controlled ovarian stimulation — and, unlike GnRH agonists, it does so without an initial flare-up of gonadotropins. UPOR Biotech supplies ganirelix acetate as Research Grade (RUO) material only.
Both are decapeptide GnRH antagonists that block the premature LH surge, but they differ in structure and research positioning: ganirelix (ORG 37462) carries diethyl-arginine (hArg(Et₂)) substitutions at positions 6 and 8 and is the standard antagonist for controlled ovarian hyperstimulation research, whereas cetrorelix (SB-75) has a broader profile spanning oncology research, including investigation in hormone-dependent tumors. UPOR Biotech supplies both as Research Grade (RUO) peptides.
Core applications include: IVF and controlled ovarian hyperstimulation (COH) research, where ganirelix prevents premature ovulation; premature LH surge prevention studies; hormone-sensitive cancer research, via modulation of GnRH-mediated gonadotropin signaling; and HPGA pharmacology — probing hypothalamic-pituitary-gonadal feedback. Ganirelix also serves as a gonadotropin assay reference and analytical standard in reproductive endocrinology.
Store the lyophilized powder at -20°C, desiccated and protected from light, for up to 2 years. Reconstitute in water, sterile saline, or aqueous buffer at physiological pH immediately before use; avoid repeated freeze-thaw cycles — aliquot and snap-freeze any remaining solution. For research dosing, DMSO may be used for concentrated stock solutions with subsequent aqueous dilution.
Every shipment includes: COA (HPLC purity ≥98.0%, peptide content, endotoxin ≤1.0 EU/mg), MSDS, HPLC chromatogram, MS confirmation, and endotoxin analysis. Manufacturing is performed under ISO 9001, cGMP, and FDA facility registration. All ganirelix acetate is supplied as Research Use Only (RUO) material — not for human diagnostic or therapeutic use.